ODI Pharma AB (XSAT:ODI) 5-Year Yield-on-Cost %: 0.00 (As of Aug. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:ODI ODI Pharma AB XSAT:ODI
46 GF Score
Price kr2.42
GF Value kr9.68
Valuation Significantly Undervalued
View Full Analysis

What is ODI Pharma AB 5-Year Yield-on-Cost %?

ODI Pharma AB XSAT:ODI -8.33% 46 5-Year Yield-on-Cost % is 0.00 as of Aug. 16, 2026. GuruFocus rates XSAT:ODI with a GF Score™ of 46/100 and a GF Value™ of kr9.68 (Significantly Undervalued). Among 510 Drug Manufacturers companies, ODI Pharma AB ranks worse than 196078.24% on this metric.

ODI Pharma AB's yield on cost for the quarter that ended in Mar. 2026 was 0.00.


The historical rank and industry rank for ODI Pharma AB's 5-Year Yield-on-Cost % or its related term are showing as below:



XSAT:ODI's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.285
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

ODI Pharma AB  (XSAT:ODI) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


ODI Pharma AB 5-Year Yield-on-Cost % Related Terms


XSAT:ODI vs ZTS, UTHR, VTRS: 5-Year Yield-on-Cost % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, ODI Pharma AB's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ODI Pharma AB 5-Year Yield-on-Cost % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ODI Pharma AB's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where ODI Pharma AB's 5-Year Yield-on-Cost % falls into.


XSAT:ODI
46GF Score
ODI Pharma AB XSAT:ODI
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ODI Pharma AB 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of ODI Pharma AB is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
ODI Pharma AB (XSAT:ODI) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 16, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on ODI Pharma AB and its competitors. According to the industry distribution chart, ODI Pharma AB ranks #999999 out of 510 companies in the Drug Manufacturers industry.
Is ODI Pharma AB's 5-Year Yield-on-Cost % too high?
ODI Pharma AB's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, ODI Pharma AB ranks #999999 out of 510 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, ODI Pharma AB has a GF Score™ of 46/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ODI Pharma AB's 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ODI Pharma AB ranks #999999 out of 510 companies for 5-Year Yield-on-Cost %. This places ODI Pharma AB in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.29, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on ODI Pharma AB and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ODI Pharma AB's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ODI Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, ODI Pharma AB (XSAT:ODI) is currently considered Significantly Undervalued. The stock's GF Value™ is kr9.68, compared to a current price of kr2.42 — trading 75% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. ODI Pharma AB's overall GF Score™ is 46/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For ODI Pharma AB (XSAT:ODI), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ODI Pharma AB (XSAT:ODI) Overvalued in 2026?

Based on GuruFocus' analysis, ODI Pharma AB stock appears to be undervalued. The current stock price of kr2.42 is trading 75% below its estimated GF Value™ of kr9.68. GuruFocus considers ODI Pharma AB to be Significantly Undervalued.

Key valuation signals for XSAT:ODI:

  • 5-Year Yield-on-Cost %: 0.00
  • GF Value™: kr9.68 vs. price of kr2.42 (75% below fair value)
  • GF Score™: 46/100

No single metric tells the full story. See the XSAT:ODI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ODI Pharma AB Business Description

Address Ostermalmstorg 1, Stockholm, SWE, 114 42
ODI Pharma AB is a provider of medicinal cannabis. It offers its products to pharmacies, specialty clinics, and hospitals.
46GF Score

Get the complete analysis for XSAT:ODI

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr2.42
Price
kr9.68
GF Value